drugset / Trial / NCT04144257

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

NCT04144257

NaSingle-groupOpen-labelDiagnostic

Summary

The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, \[F-18\]PBR06 and \[C-11\]MRB. Specific Aims: Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed by \[F-18\]PBR06 PET, with MS-related fatigue. Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as assessed by \[C-11\]MRB PET, with MS-related fatigue. Specific Aim 3: To determine the relationship of microglial activation and NET binding, with grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate their independent contribution in development of MS-related fatigue.

Timeline

Start
2020-03-12
Primary completion
2021-04-13
Completion
2021-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject [C-11]Methylreboxetine Diagnostic / imaging agent
Subject [F-18]PBR06 Diagnostic / imaging agent

Indications